FATE - Fate Therapeutics GAAP EPS of -$0.86 beats by $0.04 revenue of $14.98M misses by $0.51M
- Fate Therapeutics press release ( NASDAQ: FATE ): Q3 GAAP EPS of -$0.86 beats by $0.04 .
- Revenue of $14.98M (+5.3% Y/Y) misses by $0.51M .
- Cash, cash equivalents and investments as of September 30, 2022 were $519.1 million.
For further details see:
Fate Therapeutics GAAP EPS of -$0.86 beats by $0.04, revenue of $14.98M misses by $0.51M